2019³â Áß¾Ó´ëÇб³º´¿ø ºñ´¢ÀÇÇаú Ãß°è ½ÉÆ÷Áö¿ò : 2019-11-22±³À°ÀÏÀÚ : 2019-11-22
±³À°Àå¼Ò : Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç
±³À°ÁÖÁ¦ :
2019³â Áß¾Ó´ëÇб³º´¿ø ºñ´¢ÀÇÇаú Ãß°è ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : Áß¾Ó´ëÇб³º´¿ø
´ã´çÀÚ : ÃÖ¼¼¿µ
¿¬¶ôó : 02-6299-1810
À̸ÞÀÏ :
alse3025@hanmail.net ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 20¸í
Èñ¸ÁÆòÁ¡ : 1Á¡
Áö¿ª :
¼¿ïƯº°½Ã ±³À°½Ã°£ : 1 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í - »çÀü µî·Ï¸¸ °¡´É(À̸ÞÀÏ ½Åû / 10¿ù 31ÀϱîÁö)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-22 Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç 15:30~15:45 The recent updates of bone targeted agents for mCRPC ÀåÀÎÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-22 Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç 15:45~16:00 Chronic Prostatitis and CPPS: The never-ending story ±èÅÂÇü(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-22 Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç 16:00~16:15 Renal cell carcinoma: Prognostic models and markers update ÃÖ¼¼¿µ(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 11-22 Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç 16:15~16:45 GnRH Agonist in Prostate Cancer ±èÁø¿í(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-22 Áß¾Ó´ëÇб³º´¿ø 4Ãþ¼¼¹Ì³ª½Ç 16:45~17:00 Prostate cancer: Active Surveillance Follow-Up Áöº´ÈÆ(Á߾Ӵ뺴¿ø)